Noxopharm Limited (ASX:NOX)
Share Pricing & News Healthcare

AUD 0.245

0.015 (6.522%)
(As on 2022-08-15 19:57:13 AEDT)
Previous Close Open Close*
0.23 0.24 0.245
Market Cap Dividend Yield (Annualized)
AUD 71.598M 0.00%

Day Range
0.235L 0.245 H
52 WEEK HIGH LOW
0.17L 0.63 H

Chart Price & Information

Last Trade 0.245
Change% 6.5217
52 W H/L 0.630/0.170
EBITDA -9.629M
NPAT After Abnormal Items -9.347M
Equity 40.776M
ROE% -22.92%
Total Liabilities 7.077M
Total Revenue 14.432M
Cash and Cash Equivalents 26.796M

Stock Information

Share price 0.245
Market Cap 71.598M
Price/Gross Cash Flow -38.34
Dividend Yield Excluding Special 0.00%
Ending Shares 288.222M
52-Week Range 0.630-0.170
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 3.040
Net Tangible Asset (NTA) 0.14
P/E ratio 32.895
Sector P/E --
EPS -3.54
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.02
Net Gearing -64.86%
Sales Per Share 0.00
Book Value Per Share 0.14

Similar Companies

Related Articles

About Company

Noxopharm Limited is an ASX-listed clinical-stage drug development company focused on the potential treatment of a wide range of cancers. The company operates under the healthcare sector and aims to create unique anti-cancer drugs. It is backed by a solid pipeline of drug candidates including Veyonda®, the first oncology pipeline product. Housed in the non-oncology subsidiary, Nyrada Inc. are four pre-clinical R and D programs.

Corporate Information


Suite 3 Level 4, 828 Pacific Highway, GORDON, NSW, AUSTRALIA, 2072

Phone:(02) 9144 2223

Website:http://www.noxopharm.com

Dividends

Ex-Date Net Dividend Frank Flag Period End Date Type Payable

Event Calendar

Event Type Event Date Event Year
Report (Interim) 2023-02-20 2023
Report (Annual) 2022-09-09 2022
Report (Annual) 2022-08-25 2022
Report (Prelim) 2022-08-25 2022